{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:34:23Z","timestamp":1792791263824,"version":"4.5.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T00:00:00Z","timestamp":1771632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"vor","delay-in-days":39,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Ashoka University for PhD fellowship","id":[{"id":"https:\/\/ror.org\/02j1xr113","id-type":"ROR","asserted-by":"crossref"}]},{"name":"DST-JC Bose Research Fellowship"},{"name":"Mphasis grant"},{"name":"Bajaj Auto Ltd."},{"name":"DBT-Ramalingaswami 're-entry\u2019 fellowship"},{"name":"DBT-Basic Research in Biology awarded by DBT-India"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-40913-9","type":"journal-article","created":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T11:34:10Z","timestamp":1771673650000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["EGFR and AR expression and co-expression in Indian triple-negative breast cancer with patient outcome association"],"prefix":"10.1038","volume":"16","author":[{"given":"Pooja","family":"Vaid","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anirudha","family":"Puntambekar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pranali","family":"Kanse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shweta","family":"Kadu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piyush","family":"Agrawal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditi","family":"Khatpe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rituja","family":"Banale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruhi","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devaki A.","family":"Kelkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sridhar","family":"Hannenhalli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. S.","family":"Shashidhara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaitanyanand","family":"Koppiker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madhura","family":"Kulkarni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,21]]},"reference":[{"issue":"15","key":"40913_CR1","doi-asserted-by":"publisher","first-page":"4429","DOI":"10.1158\/1078-0432.CCR-06-3045","volume":"13","author":"R Dent","year":"2007","unstructured":"Dent, R. et al. Triple-negative breast cancer: Clinical features and patterns of recurrence. Clin. Cancer Res. 13 (15), 4429\u20134434. https:\/\/doi.org\/10.1158\/1078-0432.CCR-06-3045 (2007).","journal-title":"Clin. Cancer Res."},{"issue":"20","key":"40913_CR2","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1056\/NEJMra1001389","volume":"363","author":"WD Foulkes","year":"2010","unstructured":"Foulkes, W. D., Smith, I. E. & Reis-Filho, J. S. Triple-negative breast cancer. N Engl. J. Med. 363 (20), 1938\u20131948. https:\/\/doi.org\/10.1056\/NEJMra1001389 (2010).","journal-title":"N Engl. J. Med."},{"issue":"1","key":"40913_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-019-51335-1","volume":"9","author":"MV Fournier","year":"2019","unstructured":"Fournier, M. V. et al. A Predictor of Pathological Complete Response to Neoadjuvant Chemotherapy Stratifies Triple Negative Breast Cancer Patients with High Risk of Recurrence. Sci. Rep. 9 (1), 1\u20139. https:\/\/doi.org\/10.1038\/s41598-019-51335-1 (2019).","journal-title":"Sci. Rep."},{"key":"40913_CR4","doi-asserted-by":"publisher","unstructured":"Kulkarni, A. et al. Meta-Analysis of Prevalence of Triple-Negative Breast Cancer and Its Clinical Features at Incidence in Indian Patients With Breast Cancer. JCO Glob Oncol. (6), 1052\u20131062. https:\/\/doi.org\/10.1200\/go.20.00054 (2020).","DOI":"10.1200\/go.20.00054"},{"issue":"April","key":"40913_CR5","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1007\/s13193-020-01253-w","volume":"12","author":"PK Jonnada","year":"2021","unstructured":"Jonnada, P. K., Sushma, C., Karyampudi, M. & Dharanikota, A. Prevalence of Molecular Subtypes of Breast Cancer in India: a Systematic Review and Meta-analysis. Indian J. Surg. Oncol. 12 (April), 152\u2013163. https:\/\/doi.org\/10.1007\/s13193-020-01253-w (2021).","journal-title":"Indian J. Surg. Oncol."},{"key":"40913_CR6","doi-asserted-by":"publisher","unstructured":"Suvobrata, S. & Murtaza, A. Triple Negative Breast Cancer Prevalence in Indian Patients over a Decade: A Systematic Review. Int. J. Clin. Biostat Biometrics. 8 (1). https:\/\/doi.org\/10.23937\/2469-5831\/1510045 (2022).","DOI":"10.23937\/2469-5831\/1510045"},{"issue":"4","key":"40913_CR7","doi-asserted-by":"publisher","first-page":"505","DOI":"10.4103\/ijc.ijc_1120_21","volume":"60","author":"RK Sharma","year":"2023","unstructured":"Sharma, R. K. et al. Dose\u2013dense neoadjuvant chemotherapy in triple\u2013negative breast cancer: Real\u2013world data from a developing country. Indian J. Cancer. 60 (4), 505\u2013511. https:\/\/doi.org\/10.4103\/ijc.ijc_1120_21 (2023).","journal-title":"Indian J. Cancer"},{"issue":"7","key":"40913_CR8","doi-asserted-by":"publisher","first-page":"2750","DOI":"10.1172\/JCI45014","volume":"121","author":"BD Lehmann","year":"2011","unstructured":"Lehmann, B. D. et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J. Clin. Invest. 121 (7), 2750\u20132767. https:\/\/doi.org\/10.1172\/JCI45014 (2011).","journal-title":"J. Clin. Invest."},{"issue":"6","key":"40913_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0157368","volume":"11","author":"BD Lehmann","year":"2016","unstructured":"Lehmann, B. D. et al. Refinement of triple-negative breast cancer molecular subtypes: Implications for neoadjuvant chemotherapy selection. PLoS One. 11 (6), 1\u201322. https:\/\/doi.org\/10.1371\/journal.pone.0157368 (2016).","journal-title":"PLoS One"},{"key":"40913_CR10","doi-asserted-by":"publisher","unstructured":"Masuda, H. et al. Role of epidermal growth factor receptor in breast cancer. Breast Cancer Res. Treat Published online 2012. https:\/\/doi.org\/10.1007\/s10549-012-2289-9","DOI":"10.1007\/s10549-012-2289-9"},{"key":"40913_CR11","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.anndiagpath.2017.01.009","volume":"28","author":"AE Abdelrahman","year":"2017","unstructured":"Abdelrahman, A. E., Rashed, H. E., Abdelgawad, M. & Abdelhamid, M. I. Prognostic impact of EGFR and cytokeratin 5\/6 immunohistochemical expression in triple-negative breast cancer. Ann. Diagn. Pathol. 28, 43\u201353. https:\/\/doi.org\/10.1016\/j.anndiagpath.2017.01.009 (2017).","journal-title":"Ann. Diagn. Pathol."},{"key":"40913_CR12","doi-asserted-by":"publisher","unstructured":"Zhang, L. et al. Androgen receptor, EGFR, and BRCA1 as biomarkers in triple-negative breast cancer: A meta-analysis. Biomed. Res. Int. 2015 (Im). https:\/\/doi.org\/10.1155\/2015\/357485 (2015).","DOI":"10.1155\/2015\/357485"},{"key":"40913_CR13","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-011-9827-x","author":"D Liu","year":"2012","unstructured":"Liu, D. et al. EGFR expression correlates with decreased disease-free survival in triple-negative breast cancer: A retrospective analysis based on a tissue microarray. Med Oncol Published online. https:\/\/doi.org\/10.1007\/s12032-011-9827-x (2012).","journal-title":"Med Oncol Published online"},{"issue":"3","key":"40913_CR14","doi-asserted-by":"publisher","first-page":"181","DOI":"10.21873\/cgp.20030","volume":"14","author":"S Levva","year":"2017","unstructured":"Levva, S. et al. Prognostic evaluation of epidermal growth factor receptor (EGFR) genotype and phenotype parameters in triple-negative breast cancers. Cancer Genomics Proteom. 14 (3), 181\u2013195. https:\/\/doi.org\/10.21873\/cgp.20030 (2017).","journal-title":"Cancer Genomics Proteom."},{"key":"40913_CR15","doi-asserted-by":"publisher","first-page":"100409","DOI":"10.1016\/j.ctarc.2021.100409","volume":"28","author":"L Busheri","year":"2021","unstructured":"Busheri, L. et al. Breast cancer biobank from a single institutional cohort in an urban setting in india: Tumor characteristics and survival outcomes. Cancer Treat. Res. Commun. 28, 100409. https:\/\/doi.org\/10.1016\/j.ctarc.2021.100409 (2021).","journal-title":"Cancer Treat. Res. Commun."},{"issue":"8","key":"40913_CR16","first-page":"515","volume":"70","author":"B Cancer","year":"2016","unstructured":"National Comprehensive Cancer Network & Cancer, B. Version 4.2017 \u2014 February 7, 2018. J. R Soc. Med. 70 (8), 515\u2013517 (2016). https:\/\/www2.tri-kobe.org\/nccn\/guideline\/breast\/english\/breast.pdf","journal-title":"J. R Soc. Med."},{"issue":"4","key":"40913_CR17","doi-asserted-by":"publisher","first-page":"452","DOI":"10.6004\/jnccn.2020.0016","volume":"18","author":"National Comprehensive Cancer Network","year":"2020","unstructured":"National Comprehensive Cancer Network. Breast Cancer Version 32020 ;18(4):452\u2013478. doi:https:\/\/doi.org\/10.6004\/jnccn.2020.0016 (2020).","journal-title":"Breast Cancer Version 32020"},{"issue":"2","key":"40913_CR18","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.cell.2018.02.052","volume":"173","author":"J Liu","year":"2018","unstructured":"Liu, J. et al. An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics. Cell 173 (2), 400\u2013416e11. https:\/\/doi.org\/10.1016\/j.cell.2018.02.052 (2018).","journal-title":"Cell"},{"key":"40913_CR19","doi-asserted-by":"publisher","unstructured":"Venkatasubramanian, G., Kelkar, D. A., Mandal, S., Jolly, M. K. & Kulkarni, M. Analysis of Yes-Associated Protein-1 (YAP1) Target Gene Signature to Predict Progressive Breast Cancer. J. Clin. Med. 11 (7). https:\/\/doi.org\/10.3390\/jcm11071947 (2022).","DOI":"10.3390\/jcm11071947"},{"issue":"9","key":"40913_CR20","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1038\/s41588-021-00911-1","volume":"53","author":"SZ Wu","year":"2021","unstructured":"Wu, S. Z. et al. A single-cell and spatially resolved atlas of human breast cancers. Nat. Genet. 53 (9), 1334\u20131347. https:\/\/doi.org\/10.1038\/s41588-021-00911-1 (2021).","journal-title":"Nat. Genet."},{"issue":"9","key":"40913_CR21","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1038\/s41422-020-0355-0","volume":"30","author":"J Qian","year":"2020","unstructured":"Qian, J. et al. A pan-cancer blueprint of the heterogeneous tumor microenvironment revealed by single-cell profiling. Cell. Res. 30 (9), 745\u2013762. https:\/\/doi.org\/10.1038\/s41422-020-0355-0 (2020).","journal-title":"Cell. Res."},{"issue":"9","key":"40913_CR22","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1038\/s41588-021-00911-1","volume":"53","author":"SZ Wu","year":"2021","unstructured":"Wu, S. Z. et al. A single-cell and spatially resolved atlas of human breast cancers. Nat. Genet. 53 (9), 1334\u20131347. https:\/\/doi.org\/10.1038\/s41588-021-00911-1 (2021).","journal-title":"Nat. Genet."},{"issue":"1","key":"40913_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1472-6890-12-18","volume":"12","author":"SK Kanapathy Pillai","year":"2012","unstructured":"Kanapathy Pillai, S. K., Tay, A., Nair, S. & Leong, C. O. Triple-negative breast cancer is associated with EGFR, CK5\/6 and c-KIT expression in Malaysian women. BMC Clin. Pathol. 12 (1), 1. https:\/\/doi.org\/10.1186\/1472-6890-12-18 (2012).","journal-title":"BMC Clin. Pathol."},{"issue":"9","key":"40913_CR24","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1038\/modpathol.2013.251","volume":"27","author":"HS Park","year":"2014","unstructured":"Park, H. S. et al. High EGFR gene copy number predicts poor outcome in triple-negative breast cancer. Mod. Pathol. 27 (9), 1212\u20131222. https:\/\/doi.org\/10.1038\/modpathol.2013.251 (2014).","journal-title":"Mod. Pathol."},{"issue":"8","key":"40913_CR25","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1093\/annonc\/mdq678","volume":"22","author":"S Park","year":"2011","unstructured":"Park, S. et al. Androgen receptor expression is significantly associated with better outcomes in estrogen receptor-positive breast cancers. Ann. Oncol. 22 (8), 1755\u20131762. https:\/\/doi.org\/10.1093\/annonc\/mdq678 (2011).","journal-title":"Ann. Oncol."},{"issue":"2","key":"40913_CR26","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1007\/s12032-011-9948-2","volume":"29","author":"D Tang","year":"2012","unstructured":"Tang, D., Xu, S., Zhang, Q. & Zhao, W. The expression and clinical significance of the androgen receptor and E-cadherin in triple-negative breast cancer. Med. Oncol. 29 (2), 526\u2013533. https:\/\/doi.org\/10.1007\/s12032-011-9948-2 (2012).","journal-title":"Med. Oncol."},{"issue":"2","key":"40913_CR27","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1245\/s10434-013-3260-7","volume":"21","author":"LJ McGhan","year":"2014","unstructured":"McGhan, L. J. et al. Androgen receptor-positive triple negative breast cancer: A unique breast cancer subtype. Ann. Surg. Oncol. 21 (2), 361\u2013367. https:\/\/doi.org\/10.1245\/s10434-013-3260-7 (2014).","journal-title":"Ann. Surg. Oncol."},{"issue":"3","key":"40913_CR28","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.3390\/cancers6031351","volume":"6","author":"M Pistelli","year":"2014","unstructured":"Pistelli, M. et al. Androgen receptor expression in early triple-negative breast cancer: Clinical significance and prognostic associations. Cancers (Basel). 6 (3), 1351\u20131362. https:\/\/doi.org\/10.3390\/cancers6031351 (2014).","journal-title":"Cancers (Basel)"},{"issue":"2","key":"40913_CR29","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1007\/s12032-011-9832-0","volume":"29","author":"J He","year":"2012","unstructured":"He, J. et al. Prognostic value of androgen receptor expression in operable triple-negative breast cancer: A retrospective analysis based on a tissue microarray. Med. Oncol. 29 (2), 406\u2013410. https:\/\/doi.org\/10.1007\/s12032-011-9832-0 (2012).","journal-title":"Med. Oncol."},{"issue":"3","key":"40913_CR30","doi-asserted-by":"publisher","first-page":"48","DOI":"10.21276\/iabcr.2017.3.3.13","volume":"3","author":"AK Saxena","year":"2017","unstructured":"Saxena, A. K., Agarwal, M., Singhal, J. & Gupta, A. Evaluation of Androgen Receptor in Breast Carcinoma and its Correlations with Er, Pr, Her2\/Neu, Triple Negative Receptor Status and Clinical Parameters. Int. Arch. Biomed. Clin. Res. 3 (3), 48\u201351. https:\/\/doi.org\/10.21276\/iabcr.2017.3.3.13 (2017).","journal-title":"Int. Arch. Biomed. Clin. Res."},{"issue":"1","key":"40913_CR31","doi-asserted-by":"publisher","first-page":"28","DOI":"10.4103\/ijmpo.ijmpo_4_17","volume":"39","author":"R Patnayak","year":"2018","unstructured":"Patnayak, R., Jena, A., Bhargavi, D. & Chowhan, A. Androgen receptor expression in triple negative breast cancer - Study from a tertiary health care center in South India. Indian J. Med. Paediatr. Oncol. 39 (1), 28\u201331. https:\/\/doi.org\/10.4103\/ijmpo.ijmpo_4_17 (2018).","journal-title":"Indian J. Med. Paediatr. Oncol."},{"issue":"5","key":"40913_CR32","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1158\/1078-0432.CCR-07-1658","volume":"14","author":"MCU Cheang","year":"2008","unstructured":"Cheang, M. C. U. et al. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin. Cancer Res. 14 (5), 1368\u20131376. https:\/\/doi.org\/10.1158\/1078-0432.CCR-07-1658 (2008).","journal-title":"Clin. Cancer Res."},{"key":"40913_CR33","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.semcancer.2020.06.005","volume":"72","author":"F Borri","year":"2021","unstructured":"Borri, F. & Granaglia, A. Pathology of triple negative breast cancer. Semin Cancer Biol. 72, 136\u2013145. https:\/\/doi.org\/10.1016\/j.semcancer.2020.06.005 (2021).","journal-title":"Semin Cancer Biol."},{"issue":"3","key":"40913_CR34","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1038\/modpathol.2013.145","volume":"27","author":"AA Thike","year":"2014","unstructured":"Thike, A. A. et al. Loss of androgen receptor expression predicts early recurrence in triple-negative and basal-like breast cancer. Mod. Pathol. 27 (3), 352\u2013360. https:\/\/doi.org\/10.1038\/modpathol.2013.145 (2014).","journal-title":"Mod. Pathol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-40913-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-40913-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-40913-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T23:05:06Z","timestamp":1775084706000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-40913-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,21]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["40913"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-40913-9","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,21]]},"assertion":[{"value":"3 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The studies involving humans were approved by the ethical committee at Prashanti Cancer Care Mission. The studies were conducted in accordance with the local legislation and institutional requirements. The participants provided their written informed consent to participate in this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics statement"}}],"article-number":"11010"}}